BioAlliance Pharma, pivotal phase III clinical trial of Loramyc , treatment of oropharyngeal candidiasis

Paris, November 16, 2007 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc® in the US, for the treatment of oropharyngeal candidiasis... [PDF] BioAlliance's Press Release - PDF en Français -